1. Search Result
Search Result
Results for "

large non-structural protein 3 (nsp3)

" in MedChemExpress (MCE) Product Catalog:

318

Inhibitors & Agonists

26

Screening Libraries

14

Fluorescent Dye

24

Biochemical Assay Reagents

38

Peptides

4

MCE Kits

10

Inhibitory Antibodies

32

Natural
Products

191

Recombinant Proteins

12

Isotope-Labeled Compounds

48

Antibodies

2

Click Chemistry

11

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150062

    SARS-CoV Infection
    SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
    SARS-CoV-2 nsp3-IN-1
  • HY-122671

    Anion Exchangers Neurological Disease
    OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1
  • HY-117411A

    KW-136 dihydrochloride

    HCV HCV Protease Infection
    Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .
    Coblopasvir dihydrochloride
  • HY-156597

    AT-752 free base

    SARS-CoV Infection
    Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .
    Arbemnifosbuvir
  • HY-U00462

    Hexokinase Metabolic Disease
    D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization of carbohydrate in rat [3].
    D-Mannoheptulose
  • HY-150064

    SARS-CoV Infection
    SARS-CoV-2 nsp3-IN-2 is a macrodomain (Mac1) inhibitor with IC50 value of 180 μM. SARS-CoV-2 nsp3-IN-2 is a small molecule chemical probe and can be used for the research of viral .
    SARS-CoV-2 nsp3-IN-2
  • HY-163785

    SARS-CoV Infection
    1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
    1
  • HY-157439

    SARS-CoV Infection
    SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-COV-2 papain-like protease domain that can trigger the degradation of NSP3 .
    SARS-CoV-2-IN-72
  • HY-117411

    KW-136

    HCV HCV Protease Infection Inflammation/Immunology
    Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .
    Coblopasvir
  • HY-E70216

    Others Others
    Bsu DNA polymerase, Large fragment is a polymerase derived from Bacillus subtilis. Bsu DNA polymerase, Large fragment is a DNA isothermal amplification polymerase with chain replacement activity, which used in RPA recombinase polymerase amplification technology .
    Bsu DNA polymerase, Large fragment
  • HY-P10403

    IGF-1R Inflammation/Immunology Cancer
    IGFBP-3 peptide is a 18-amino acid insulin-like growth factor binding protein-3. IGFBP-3 peptide binds Humanin (HY-P1928) and Hyaluronan (HY-B0633A), blocks the interaction of CD44 and hyaluronan .
    IGFBP-3 peptide
  • HY-122671S

    Anion Exchangers Neurological Disease
    OB-1-d3 is the deuterium labeled OB-1 (HY-122671). OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1-d3
  • HY-U00462S

    Isotope-Labeled Compounds Metabolic Disease
    D-Mannoheptulose- 13C is the 13C labeled D-Mannoheptulose. D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization
    D-Mannoheptulose-13C
  • HY-169998

    SARS-CoV Infection
    XJ5 is a non-nucleoside covalent inhibitor of Nsp12 (IC50=0.12 μM), which is the non-structural protein 12 of the virus. XJ5 has the potential to be an antiviral inhibitor of SARS-CoV-2 .
    XJ5
  • HY-RS07525

    Small Interfering RNA (siRNA) Others

    LARGE2 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LARGE2 Human Pre-designed siRNA Set A
    LARGE2 Human Pre-designed siRNA Set A
  • HY-RS07524

    Small Interfering RNA (siRNA) Others

    LARGE1 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LARGE1 Human Pre-designed siRNA Set A
    LARGE1 Human Pre-designed siRNA Set A
  • HY-150623

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
    SARS-CoV-2 nsp13-IN-2
  • HY-150624

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
    SARS-CoV-2 nsp13-IN-3
  • HY-W107409

    Others Cancer
    Meridianin C is a marine natural product with anticancer activity. Meridianin C has significant inhibitory effects on four different human tongue cancer cells (YD-8, YD-10B, YD-38 and HSC-3). Meridianin C most strongly reduced the growth of YD-10B cells, the most aggressive and tumorigenic of the cell lines tested. Meridianin C also induced significant accumulation of large vesicles in YD-10B cells, validating its function through macrophagocytosis. Meridianin C reduces cellular levels of Dickkopf-related protein-3 (DKK-3), a known negative regulator of macrophagy. Meridianin C affects macrophagocytosis by downregulating DKK-3, thereby affecting cell proliferation .
    Meridianin C
  • HY-169102

    Virus Protease Infection
    CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structural protein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .
    CHIKV nsP2 protease-IN-1
  • HY-150632

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
    SARS-CoV-2 nsp13-IN-6
  • HY-170649

    SARS-CoV Infection
    RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
    RdRP-IN-9
  • HY-150622

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
    SARS-CoV-2 nsp13-IN-1
  • HY-171131

    Btk Cancer
    BTK-IN-41 (Compound 47) is the inhibitor for BTK with an IC50 of 5.4 nM. BTK-IN-41 inhibits the diffuse large B cell lymphoma cell TDM-8 with IC50 of 13.8 nM .
    BTK-IN-41
  • HY-132253

    Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin
  • HY-12594
    Paritaprevir
    10+ Cited Publications

    ABT-450; Veruprevir

    HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [3] .
    Paritaprevir
  • HY-132253A

    Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin (solution)
  • HY-12594A

    ABT-450 dihydrate; Veruprevir dihydrate

    HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) [3] .
    Paritaprevir dihydrate
  • HY-150594

    IRAK NF-κB Cancer
    IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .
    IRAK4-IN-17
  • HY-161080

    Nucleoside Antimetabolite/Analog Cancer
    4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .
    4'-Ethynyl-2'-deoxycytidine
  • HY-10300
    Narlaprevir
    4 Publications Verification

    SCH 900518

    HCV HCV Protease SARS-CoV Infection
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM [3].
    Narlaprevir
  • HY-155574

    IRAK Apoptosis Cancer
    IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC50 of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .
    IRAK4-IN-27
  • HY-131246

    Histone Methyltransferase Cancer
    DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .
    DM-01
  • HY-P99349

    Loncastuximab tesirine-lpyl; ADCT-402

    Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
    Loncastuximab tesirine
  • HY-12422

    CDK Cancer
    Voruciclib is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .
    Voruciclib
  • HY-12422A

    CDK Cancer
    Voruciclib hydrochloride is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .
    Voruciclib hydrochloride
  • HY-144858
    EZM0414
    5+ Cited Publications

    Histone Methyltransferase Cancer
    EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
    EZM0414
  • HY-145734A

    Microtubule/Tubulin Cancer
    AMXI-5001 hydrochloride is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001 hydrochloride
  • HY-145734

    Microtubule/Tubulin Cancer
    AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001
  • HY-14775
    Nesbuvir
    5+ Cited Publications

    HCV-796

    HCV Infection
    Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
    Nesbuvir
  • HY-146408

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC50 values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK WT, ALK L1196M and ALK G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC50 values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma .
    ALK-IN-21
  • HY-144293

    Apoptosis HDAC Cancer
    HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma .
    HDAC-IN-31
  • HY-P4882

    Amyloid-β Neurological Disease
    (Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
    (Pyr3)-Amyloid β-Protein (3-42)
  • HY-147358A

    Emitasvir; DAG-181

    HCV Infection
    Yimitasvir (Emitasvir) is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor. Yimitasvir can be used for research of chronic HCV infection .
    Yimitasvir
  • HY-P4882A

    Amyloid-β Neurological Disease
    (Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
    (Pyr3)-Amyloid β-Protein (3-42) (TFA)
  • HY-153810

    JNJ-1802

    Virus Protease Flavivirus Dengue Virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-161765

    HSP STAT Cancer
    iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
    iHSP110-33
  • HY-147358

    Emitasvir diphosphate; DAG-181 diphosphate

    HCV Infection
    Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .
    Yimitasvir diphosphate
  • HY-147358C

    (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate

    HCV Infection
    Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .
    (1R,4S)-Yimitasvir diphosphate
  • HY-122595

    Histone Methyltransferase Cancer
    EZH2-IN-1 (compound 3) is a selective and SAM-competitive EZH2 and EZH1 inhibitor with an IC50s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research .
    EZH2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: